Drugs / IPM001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05105815 | Dec 2021 → Dec 2023 | hepatocellular carcinoma | Huashan Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05536427 | Oct 2022 → Oct 2024 | hepatocellular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPM001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05536427 ↗ |
| Modality | Cell therapy | “neoantigen/tumor-specific antigen sensitized autoimmune cell injection” NCT05105815 ↗ |